Literature DB >> 23182608

A dose-response study of remifentanil for attenuation of the hypertensive response to laryngoscopy and tracheal intubation in severely preeclamptic women undergoing caesarean delivery under general anaesthesia.

K Y Yoo1, D H Kang, H Jeong, C W Jeong, Y Y Choi, J Lee.   

Abstract

BACKGROUND: Remifentanil is known to attenuate the cardiovascular responses to tracheal intubation. We determined effective doses (ED(50)/ED(95)) of remifentanil to prevent the pressor response to tracheal intubation in patients with severe preeclampsia.
METHODS: Seventy-five women with severe preeclampsia were randomly allocated to one of five remifentanil dose groups (0.25, 0.50, 0.75, 1.0, or 1.25 μg/kg) given before induction of anaesthesia using thiopental 5 mg/kg and suxamethonium 1.5 mg/kg. Systolic arterial pressure, heart rate and plasma catecholamine concentrations were measured. Neonatal effects were assessed by Apgar scores and umbilical cord blood gas analysis. A dose was considered effective when systolic arterial pressure did not exceed 160 mmHg for more than 1 min following tracheal intubation.
RESULTS: Baseline systolic blood pressure and heart rate did not differ among the groups. The intubation-induced increases of heart rate and blood pressure were attenuated in a dose-dependent manner by remifentanil. ED(50) and ED(95) were 0.59 (95% CI 0.47-0.70) μg/kg and 1.34 (1.04-2.19)μg/kg, respectively. Norepinephrine concentrations remained unaltered following intubation but increased significantly at delivery, with no differences between the groups. Apgar scores and umbilical arterial and venous pH and blood gas values were comparable among the groups. Two women each in the 1.0 and 1.25 μg/kg groups received ephedrine for hypotension defined as systolic arterial pressure <90 mmHg.
CONCLUSIONS: The ED(95) of remifentanil for attenuating the hypertensive response to tracheal intubation during induction of anaesthesia in severely preeclamptic patients undergoing caesarean delivery under general anaesthesia was 1.34 μg/kg.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23182608     DOI: 10.1016/j.ijoa.2012.09.010

Source DB:  PubMed          Journal:  Int J Obstet Anesth        ISSN: 0959-289X            Impact factor:   2.603


  7 in total

Review 1.  Rethinking general anesthesia for cesarean section.

Authors:  Hiroyiki Sumikura; Hidetomo Niwa; Masaki Sato; Tatsuo Nakamoto; Takashi Asai; Satoshi Hagihira
Journal:  J Anesth       Date:  2015-11-19       Impact factor: 2.078

2.  Severe preeclampsia: what's new in intensive care?

Authors:  Marc Leone; Sharon Einav
Journal:  Intensive Care Med       Date:  2015-03-03       Impact factor: 17.440

3.  Neonatal effect of remifentanil in general anaesthesia for caesarean section: a randomized trial.

Authors:  Pavlina Noskova; Jan Blaha; Hana Bakhouche; Jana Kubatova; Jitka Ulrichova; Patricia Marusicova; Jan Smisek; Antonin Parizek; Ondrej Slanar; Pavel Michalek
Journal:  BMC Anesthesiol       Date:  2015-03-26       Impact factor: 2.217

4.  Efficacy and safety of remifentanil for analgesia in cesarean delivery.

Authors:  Xuan Zhou; Lian-Jin Jin; Chun-Yang Hu; Meng Chen; Ying Li; Yue-Shun Zhang
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

5.  Pharmacological strategies to prevent haemodynamic changes after intubation in parturient women with hypertensive disorders of pregnancy: A network meta-analysis.

Authors:  Sang Won Yoon; Geun Joo Choi; Hee-Kyeong Seong; Myeong Jong Lee; Hyun Kang
Journal:  Int J Med Sci       Date:  2021-01-01       Impact factor: 3.738

6.  Comparative Evaluation of Remifentanil and Dexmedetomidine in General Anesthesia for Cesarean Delivery.

Authors:  Chengwen Li; Yandong Li; Kun Wang; Xiangang Kong
Journal:  Med Sci Monit       Date:  2015-12-07

7.  Pharmacologic strategies to prevent hemodynamic changes after intubation in parturient women with hypertensive disorders of pregnancy: A systematic review and network meta-analysis protocol.

Authors:  Sang Won Yoon; Hyun Kang; Geun Joo Choi
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.